- Home
- NSTS vs GANX Comparison
NSTS vs GANX Comparison
Compare NSTS & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NSTS | GANX |
|---|---|---|
| Founded | 1921 | 2017 |
| Country | United States | United States |
| Employees | 49 | N/A |
| Industry | Savings Institutions | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 65.9M | 78.2M |
| IPO Year | 2021 | 2021 |
Fundamental Metrics
Financial Performance| Metric | NSTS | GANX |
|---|---|---|
| Price | $13.66 | $1.75 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 4 |
| Target Price | N/A | ★ $7.50 |
| AVG Volume (30 Days) | 22.6K | ★ 495.6K |
| Earning Date | 05-13-2026 | 05-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 31.46 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $252,000.00 | $55,180.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $10.73 | $1.41 |
| 52 Week High | $13.75 | $4.34 |
Technical Indicators
Market Signals| Indicator | NSTS | GANX |
|---|---|---|
| Relative Strength Index (RSI) | 73.43 | 44.29 |
| Support Level | $11.85 | $1.73 |
| Resistance Level | $13.75 | $2.09 |
| Average True Range (ATR) | 0.06 | 0.10 |
| MACD | 0.07 | -0.01 |
| Stochastic Oscillator | 95.99 | 51.19 |
Price Performance
Historical ComparisonAbout NSTS NSTS Bancorp Inc.
NSTS Bancorp Inc is a savings and loan holding company regulated Federal Reserve Board. The company was formed to serve as the North Shore Trust and Savings stock holding company. The Bank is a wholly-owned subsidiary of the company and operates as a traditional savings institution focused on serving the banking needs of customers in market area of Lake County, Illinois and adjacent communities.
About GANX Gain Therapeutics Inc.
Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.